May 2026 Research Update

This month, Evans syndrome appeared mainly in reports involving other complex medical conditions rather than as an isolated disorder. In kidney transplant recipients exposed to alemtuzumab, autoimmune low blood counts (including Evans syndrome) could show up months to years later and often needed more than first-line treatment, while infections and blood clots were frequent concerns. Several single-patient reports also described Evans syndrome appearing together with other immune or blood disorders, where outcomes depended heavily on the broader medical context. [1] [2] [3]

In a single-center review of 40 kidney transplant recipients who developed autoimmune cytopenias after alemtuzumab induction, Evans syndrome was one of the reported forms (5 patients). The authors described two timing peaks after transplant (around 18 and 36 months) and noted that about two-thirds of patients needed second-line treatments beyond usual first steps. They also reported high rates of infections and thrombosis in this group, highlighting that managing Evans-like autoimmune blood problems after transplant can involve both controlling the cytopenias and navigating safety risks. [1]

Among the case reports, Evans syndrome was described in combination with other serious or rare conditions, which shaped how treatment played out. One older adult had Evans syndrome at the same time as immune-mediated thrombotic thrombocytopenic purpura (a clotting-related blood disorder), and although early lab markers improved with plasma exchange and steroids, treatment was later stopped as the overall condition worsened. [2] Another case involved Evans syndrome occurring during venetoclax ramp-up for chronic lymphocytic leukemia, with platelet recovery reported after rescue therapy that included romiplostim and zanubrutinib. [3]

For patients and caregivers, these studies mainly add context about when Evans syndrome can arise and what can complicate care, especially in people with transplants or blood cancers. The kidney-transplant report suggests that when Evans syndrome-like problems appear after strong immune therapies such as alemtuzumab, they may show up long after transplant and may require multiple treatment steps, while infections and clots were commonly reported in that setting. The individual case reports show that Evans syndrome can overlap with other conditions (like iTTP) or appear during other treatments, but single-patient experiences cannot predict what will happen for someone else. [1]

This month included several case reports showing how varied Evans syndrome can look when it intersects with other health needs. Across these reports, blood counts could stabilize under very different circumstances, but each success depended on a highly individualized situation. Taken together, these cases broaden the real-world picture of what Evans syndrome can coexist with and the kinds of medical planning that may be involved. [4] [5] [3]

In one toddler with Evans syndrome and mucopolysaccharidosis type II (a rare genetic enzyme disorder), hematopoietic stem cell transplantation was followed by normalized enzyme activity and stable blood counts, and the report noted no recurrence of Evans syndrome. Because this was a rare combination and a single child, it mainly shows what was possible in one unusual situation rather than a general approach for Evans syndrome. [4]

A separate report focused on Evans syndrome during major orthopedic surgery in a young woman who also had common variable immunodeficiency. The team described perioperative planning that included continuing IVIG and using preventive anticoagulation, and the patient had stable blood counts and successful bone healing without reported bleeding, clotting, or infection complications. This case helps illustrate that some people with Evans syndrome may undergo complex surgery with careful coordination across specialties. [5]

Another case involved Evans syndrome in a patient with chronic lymphocytic leukemia, where steroids, IVIG, and rituximab did not improve platelets. After romiplostim and zanubrutinib were started, the report described platelet recovery within 4 weeks and a sustained response for at least 6 months, with thrombocytopenia returning when zanubrutinib was paused and improving again after it was restarted. As a single case, it offers an early signal that some refractory situations may respond to different immune-targeting strategies, but it does not show how often this happens. [3]

For patients, these case reports are best read as examples of what has been tried in very specific circumstances, not as proof of what will work in general. They may matter most if someone has Evans syndrome alongside a rare genetic condition, needs major surgery, or has Evans syndrome in the setting of a blood cancer, because they show that stabilization has been reported in each of those situations. What remains uncertain is how common these outcomes are, which parts of the care plan were essential, and whether similar results would occur in other people. [5]